Details of the Drug Combination

General Information of Drug Combination (ID: DC1EEQD)

Drug Combination Name

Cabazitaxel Indazole derivative 5

Indication

Disease Entry	Status	REF
Adenocarcinoma	Investigative	[1]

Component Drugs

Cabazitaxel DMPAZHC

Indazole derivative 5 DMM1I8R

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: SW-620

Zero Interaction Potency (ZIP) Score: 10.94

Bliss Independence Score: 8.61

Loewe Additivity Score: 4.82

LHighest Single Agent (HSA) Score: 8.25

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Cabazitaxel

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Metastatic prostate carcinoma	N.A.	Investigative	[3]

Cabazitaxel Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[4]
------------------------------------------------------------------------------------

Cabazitaxel Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[5]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[5]
------------------------------------------------------------------------------------

Cabazitaxel Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Forkhead box protein O3 (FOXO3)	OTHXQG4P	FOXO3_HUMAN	Affects Expression	[6]
Proline-rich AKT1 substrate 1 (AKT1S1)	OT4JHN4Y	AKTS1_HUMAN	Decreases Expression	[6]
------------------------------------------------------------------------------------

Indazole derivative 5 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
ABL T315I mutant (ABL T315I)	TTZJTWA	ABL1_HUMAN	Inhibitor	[7]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)	TTIV39N	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCSUMFP	HCT-15	Investigative	[1]
Childhood T acute lymphoblastic leukemia	DC6DFCH	CCRF-CEM	Investigative	[1]
Chronic myelogenous leukemia	DCBOHYL	K-562	Investigative	[1]
Glioma	DC3TUPD	SF-268	Investigative	[1]
Melanoma	DCDOMVJ	MALME-3M	Investigative	[1]
Papillary renal cell carcinoma	DCQPLEC	ACHN	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
3	Cabazitaxel FDA Label
4	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
6	The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicol Appl Pharmacol. 2020 Aug 15;401:115091. doi: 10.1016/j.taap.2020.115091. Epub 2020 Jun 7.
7	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.